Drug Profile
Panobinostat - Novartis/Secura Bio
Alternative Names: Faridak; Farydak; LBH-589; LBH-589ALatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Icahn School of Medicine at Mount Sinai; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; Secura Bio; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
- Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II/III Chronic myeloid leukaemia
- Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
- Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease; Malignant melanoma
- Phase I Solid tumours
- No development reported Brain metastases; CNS cancer; Diffuse intrinsic pontine glioma; Gastrointestinal stromal tumours; Glioma; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
- Discontinued Cutaneous T-cell lymphoma; Prostate cancer
Most Recent Events
- 14 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Diffuse intrinsic pontine glioma (In children, In adults, In adolescents, Combination therapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(Combination therapy, In children, Second-line therapy or greater, In adults) in USA (PO, Capsule)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in France (PO)